精确激活cGAS-STING通路,使用一种新的基于的纳米激动剂来增强免疫检查点阻塞癌症免疫疗法
Yumeng Xing1,2, Ao Peng1, Jianhui Yang1
1School of Pharmacy, Anhui Medical University, Hefei, 230032, China.
Advanced science (Weinheim, Baden-Wurttemberg, Germany)
|January 17, 2024
概括
一种新的类纳米药物激活cGAS-STING通路并阻断PD-1/PD-L1,增强T细胞抗瘤免疫力. 这种方法为癌症治疗中小分子STING激动剂提供了一个有希望的替代方案.
科学领域:
- 免疫学 免疫学 免疫学
- 纳米技术纳米技术
- 癌症生物学 癌症生物学
背景情况:
- 循环GMP-AMP合成酶 (cGAS) 刺激干扰素基因 (STING) 途径对于先天免疫和癌症免疫治疗的目标至关重要.
- 目前的小分子STING激动剂面临的挑战包括低生物可用性,缺乏特异性和不良影响,限制了它们的临床应用.
- 抗微生物通过诱导线粒体DNA泄漏为STING激活提供了一个潜在的替代方案.
研究的目的:
- 开发一种新的基于的纳米药物 (MAPN),用于精确激活cGAS-STING通路并阻断PD-1/PD-L1通路,用于癌症治疗.
- 在小鼠黑色素瘤模型中研究MAPN的治疗疗效.
- 探索抗微生物作为STING激动剂的潜力.
主要方法:
- 选KLA,一种抗微生物,作为一种STING激动剂,促进线粒体DNA泄漏.
- 设计和合成一种可激活多刺激纳米药物 (MAPN),用于同时输送KLA和PD-1/PD-L1抗剂 (CVR).
- 评估MAPN在B16F10瘤携带小鼠中的抗瘤疗效,评估瘤生长抑制和存活率.
主要成果:
- 在对多个内源刺激的反应中,MAPN实现了KLA和CVR的特定部位释放.
- 同时激活cGAS-STING通路并阻断PD-1/PD-L1通路由MAPN.
- 在小鼠中,MAPN表现出显著的抗瘤作用,达到78%的瘤生长抑制率,并将中位生存时间延长到40天.
结论:
- 基于的纳米药物通过向多个途径,代表了协同癌症免疫治疗的可行策略.
- 像KLA这样的抗微生物显示出作为新型STING激动剂的前景,克服了小分子的局限性.
- MAPN 作为一个多功能平台,共同提供治疗性,增强抗瘤免疫力,并提供新的治疗途径.
更多相关视频
09:51Screening Bioactive Nanoparticles in Phagocytic Immune Cells for Inhibitors of Toll-like Receptor Signaling
Published on: July 26, 2017
12.4K
10:18Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
Published on: July 7, 2023
1.3K
相关概念视频
Tumor Immunotherapy
527
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
527
Cancer Vaccines
368
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
368
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
163
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
163
GPCRs Regulate Adenylyl Cylase Activity
5.6K
Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
5.6K
